erlotinibhttp://www.unboundmedicine.com/medline/ebm/research/erlotinibUnbound MEDLINE is a service provided by Unbound Medicine, Inc. that includes data and services from the U.S. National Library of Medicine's MEDLINE® and PubMed® databases.en-usUnbound Medicine, Inc.Radiation recall dermatitis induced by erlotinib.http://www.unboundmedicine.com/medline/ebm/record/19925938/full_citation/Radiation_recall_dermatitis_induced_by_erlotinib_Dauendorffer JN, Dupuy A 
Radiation recall dermatitis induced by erlotinib. [JOURNAL ARTICLE]
J Am Acad Dermatol 2009 Dec; 61(6):1086.
Full Citation | Find Related Articles Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer.http://www.unboundmedicine.com/medline/ebm/record/19922469/full_citation/Epidermal_growth_factor_receptor_in_relation_to_tumor_development:_EGFR_gene_and_cancer_Mitsudomi T, Yatabe Y 
Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer. [JOURNAL ARTICLE]
FEBS J 2009 Nov 18.
Abstract | Full Citation | Find Related Articles Epidermal growth factor receptor in relation to tumor development: EGFR-targeted anticancer therapy.http://www.unboundmedicine.com/medline/ebm/record/19922468/full_citation/Epidermal_growth_factor_receptor_in_relation_to_tumor_development:_EGFR_targeted_anticancer_therapy_Okamoto I 
Epidermal growth factor receptor in relation to tumor development: EGFR-targeted anticancer therapy. [JOURNAL ARTICLE]
FEBS J 2009 Nov 18.
Abstract | Full Citation | Publisher Full Text | Find Related Articles Combined inhibition of IGFR enhances the effects of gefitinib in H1650: a lung cancer cell line with EGFR mutation and primary resistance to EGFR-TK inhibitors.http://www.unboundmedicine.com/medline/ebm/record/19921194/full_citation/Combined_inhibition_of_IGFR_enhances_the_effects_of_gefitinib_in_H1650:_a_lung_cancer_cell_line_with_EGFR_mutation_and_primary_resistance_to_EGFR_TK_inhibitors_Choi YJ, Rho JK, Jeon BS, et al. 
Combined inhibition of IGFR enhances the effects of gefitinib in H1650: a lung cancer cell line with EGFR mutation and primary resistance to EGFR-TK inhibitors. [JOURNAL ARTICLE]
Cancer Chemother Pharmacol 2009 Nov 18.
Abstract | Full CitationSevere toxicity of skin rash, fever and diarrhea associated with imatinib: case report and review of skin toxicities associated with tyrosine kinase inhibitors.http://www.unboundmedicine.com/medline/ebm/record/19920908/full_citation/Severe_toxicity_of_skin_rash_fever_and_diarrhea_associated_with_imatinib:_case_report_and_review_of_skin_toxicities_associated_with_tyrosine_kinase_inhibitors_Huang X, Patel S, Ahmed N, et al. 
Severe toxicity of skin rash, fever and diarrhea associated with imatinib: case report and review of skin toxicities associated with tyrosine kinase inhibitors. [JOURNAL ARTICLE]
Drug Des Devel Ther 2009.:215-219.
Abstract | Full Citation | Find Related Articles American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer.http://www.unboundmedicine.com/medline/ebm/record/19917871/full_citation/American_Society_of_Clinical_Oncology_Clinical_Practice_Guideline_Update_on_Chemotherapy_for_Stage_IV_Non_Small_Cell_Lung_Cancer_Azzoli CG, Baker S, Temin S, et al. 
American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer. [JOURNAL ARTICLE]
J Clin Oncol 2009 Nov 16.
Abstract | Full Citation | Publisher Full Text | Find Related Articles MicroRNA Expression Profiles in Lung Cancer Cooperated with Drug Sensitivity to EGFR Tyrosine Kinase Inhibitor.http://www.unboundmedicine.com/medline/ebm/record/19915314/full_citation/MicroRNA_Expression_Profiles_in_Lung_Cancer_Cooperated_with_Drug_Sensitivity_to_EGFR_Tyrosine_Kinase_Inhibitor_Seike M 
MicroRNA Expression Profiles in Lung Cancer Cooperated with Drug Sensitivity to EGFR Tyrosine Kinase Inhibitor. [Journal Article]
J Nippon Med Sch 2009 Oct; 76(5):275-6.
Abstract | Full CitationDesign, synthesis and biological evaluation of thiazolidinone derivatives as potential EGFR and HER-2 kinase inhibitors.http://www.unboundmedicine.com/medline/ebm/record/19914835/full_citation/Design_synthesis_and_biological_evaluation_of_thiazolidinone_derivatives_as_potential_EGFR_and_HER_2_kinase_inhibitors_Lv PC, Zhou CF, Chen J, et al. 
Design, synthesis and biological evaluation of thiazolidinone derivatives as potential EGFR and HER-2 kinase inhibitors. [JOURNAL ARTICLE]
Bioorg Med Chem 2009 Oct 30.
Abstract | Full Citation | Find Related Articles Liquid chromatography-tandem mass spectrometric assay for the light sensitive tyrosine kinase inhibitor axitinib in human plasma.http://www.unboundmedicine.com/medline/ebm/record/19910267/full_citation/Liquid_chromatography_tandem_mass_spectrometric_assay_for_the_light_sensitive_tyrosine_kinase_inhibitor_axitinib_in_human_plasma_Sparidans RW, Iusuf D, Schinkel AH, et al. 
Liquid chromatography-tandem mass spectrometric assay for the light sensitive tyrosine kinase inhibitor axitinib in human plasma. [JOURNAL ARTICLE]
J Chromatogr B Analyt Technol Biomed Life Sci 2009 Oct 30.
Abstract | Full Citation | Find Related Articles Second- and Third-line Treatment of Patients With Non-Small-Cell Lung Cancer With Erlotinib in the Community Setting: Retrospective Study of Patient Healthcare Utilization and Symptom Burden.http://www.unboundmedicine.com/medline/ebm/record/19900861/full_citation/Second__and_Third_line_Treatment_of_Patients_With_Non_Small_Cell_Lung_Cancer_With_Erlotinib_in_the_Community_Setting:_Retrospective_Study_of_Patient_Healthcare_Utilization_and_Symptom_Burden_Stepanski EJ, Houts AC, Schwartzberg LS, et al. 
Second- and Third-line Treatment of Patients With Non-Small-Cell Lung Cancer With Erlotinib in the Community Setting: Retrospective Study of Patient Healthcare Utilization and Symptom Burden. [Journal Article]
Clin Lung Cancer 2009 Nov; 10(6):426-32.
Abstract | Full Citation